• On-Demand
How Do We Identify HER2+ Gastric Cancer?
  • Gastrointestinal
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • AMA PRA Category 1 Credit™
  • Participation
  • On-Demand
What’s the Best Approach to Select Targeted Treatments for HER2+ Gastric Cancer and What are Practical Considerations?
  • Gastrointestinal
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • AMA PRA Category 1 Credit™
  • Participation
  • Webinar recorded
2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management
  • Oncology
Please Note: Credit Is No Longer Available 
5
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
  • Webinar recorded
Focusing on the Role of the Advanced Bladder Cancer Care Team: Case Studies on Managing irAEs
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
  • Webinar recorded
Future Directions in Bladder Cancer Treatment: The Experts Weigh In
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
  • On-Demand
How Do Antibody-Drug Conjugates (ADCs) Fit into Precision Medicine for Gastric Cancer?
  • Gastrointestinal
  • Oncology
Please Note: Credit Is No Longer AvailableAntibody-drug conjugates or “ADCs” are a novel class of highly potent biopharmaceutical drug composed of an antibody lin
0
  • AMA PRA Category 1 Credit™
  • Participation
  • On-Demand
Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC - Medical Moment One
  • Oncology
  • Pulmonology
Please Note: Credit Is No Longer Available Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC
0
  • AMA PRA Category 1 Credit™
  • Participation
  • On-Demand
Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC - Medical Moment Two
  • Oncology
  • Pulmonology
Please Note: Credit Is No Longer Available Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Ea
0
  • AMA PRA Category 1 Credit™
  • Participation
  • On-Demand
Digging Deep into the Genome: What Genetic Testing Can (and Can’t) Tell Us about Ovarian Cancer
  • Oncology
Expert faculty for this 30-minute webinar will include a pathologist and a gynecologic oncologist.
0
  • AMA PRA Category 1 Credit™
  • Participation
  • On-Demand
Appraising Current Safety and Efficacy Data for PARP Inhibitors in Ovarian Cancer: Best Practices in Treatment and Adverse Event Management
  • Oncology
Expert faculty for this 30-minute webinar will include a gynecologic oncologist and a nurse.
0
  • AMA PRA Category 1 Credit™
  • Participation

Pages